News

RIVANNA® Announces Alliance With Tri-anim Health Services

RIVANNA®, developers of world-first, imaging-based medical solutions, announced they have entered into a partnership with Tri-anim Health Services, a specialty distributor of respiratory, anesthesia, and critical-care supplies, to represent and distribute the Accuro® portfolio of products in the United States.
RIVANNA announced a partnership with Tri-anim Health Services

Tri-anim is a natural distribution choice for RIVANNA as they provide effective and efficient patient care solutions, including innovative and proven specialty anesthesia products and consumables to support the vital role of the anesthesia provider.

Will Mauldin, Ph.D., co-founder, and CEO of RIVANNA, commented, “We worked together to establish this strategic partnership, and are excited to begin an alliance with Tri-anim due in part to their specialty anesthesia focus and clinical expertise. This milestone demonstrates an increasing opportunity for Accuro sales in the anesthesia market, and we are pleased to gain momentum across the United States. Accuro’s increased national expansion and continuing worldwide market adoption indicate RIVANNA’s success and the progression of our ongoing mission to elevate the standard of care.”

The Accuro spinal navigation system is designed to improve the efficiency of spinal needle guidance procedures using groundbreaking technology, including Multi-Frequency BoneEnhance® Image Reconstruction, which provides enhanced visualization of lumbar and thoracic bony anatomy, and SpineNav3D™AI-Based Spine Recognition, which provides automated identification of spinal midline, epidural space, and depth during lumber neuraxial anesthesia. This technology also supports real-time thoracic paramedian neuraxial procedures and prescribes a “needle-track” towards the interlaminar space. Relying on automated SpineNav3D™ technology, Accuro enables users with even minimal ultrasound experience to navigate the lumbar and thoracic spine and identify relevant landmarks used to compute, visualize and pinpoint the optimal needle insertion point.

Tom Metcalf, President of Tri-anim Health Services, said, “The Tri-anim team is thrilled to introduce this groundbreaking technology to an expanding market supporting spinal needle guidance procedures in the U.S., as it underpins Tri-anim’s vision to offer the most effective products and solutions to our customers. The Accuro is clinically proven to increase first-attempt success rates, especially with challenging patient anatomy, and will help anesthesia providers improve their efficiency and elevate their standard of care.”

Recent News

06/29/2022

Bio-plastics startup wins Lighthouse Labs pitch contest

Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!” The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate,

06/26/2022

USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual

06/20/2022

Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

New patent covers the use of the full genetic panel measuring all five genetic biomarkers CHARLOTTESVILLE, Va., — Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,351,154 was issued on June 7, 2022, by